Giuliano Filippini Velázquez

8PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersMajor global burdens of diseaseInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 07, 2026
Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.

|Oct 05, 2026
Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP.

|Nov 13, 2025
Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML.

Julian Stein, Philipp Anand, Joudi Abdulmajid

|Oct 22, 2025
Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.

Giulia Magno, Kai Rejeski, Giulia Rappa

|Sep 27, 2025
Dendritic Cells of Leukemic Origin (DCleu) Modulate the Expression of Inhibitory Checkpoint Molecules and Their Ligands on T Cells and Blasts in AML Relapse After Allogeneic Stem Cell Transplantation.

Xiaojia Feng, Giuliano Filippini Velázquez, Sophia Bohlscheid

|Apr 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.

Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib

Pageof 2

Frequent Collaborators

4 joint publications

Christoph Schmid

3 joint publications

Thomas Pabst

3 joint publications

Björn Chapuy

3 joint publications

Evgenii Shumilov